Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Indo US Bio-TechNSE:INDOUS -0.48%64 EV-to-EBIT is 12.63 as of Sep. 02, 2026, which is 58% below its 10-year median of 29.77. GuruFocus rates NSE:INDOUS with a GF Score™ of 64/100 and a GF Value™ of ₹297.03 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 204 Agriculture companies, Indo US Bio-Tech ranks worse than 53.92% on this metric.
Indo US Bio-Tech (NSE:INDOUS) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Indo US Bio-Tech's Enterprise Value for the quarter that ended in Jun. 2026 was ₹1,756 Mil.
Indo US Bio-Tech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹147 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo US Bio-Tech EV-to-EBIT Related Terms
Indo US Bio-Tech EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Indo US Bio-Tech's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:INDOUS vs CTVA, CF, MOS: EV-to-EBIT Comparison
For the Agricultural Inputs subindustry, Indo US Bio-Tech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Indo US Bio-Tech EV-to-EBIT vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Indo US Bio-Tech's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Indo US Bio-Tech's EV-to-EBIT falls into.
Indo US Bio-Tech's current Enterprise Value is ₹1,857 Mil.
Indo US Bio-Tech's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹147 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Indo US Bio-Tech (NSE:INDOUS) has a EV-to-EBIT of 12.63 as of Sep. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Indo US Bio-Tech and its competitors. This is 58% below median its historical median of 29.77. Over the past decade, Indo US Bio-Tech's EV-to-EBIT has ranged from 11.08 to 60.85. According to the industry distribution chart, Indo US Bio-Tech ranks #110 out of 204 companies in the Agriculture industry, placing it in the top 53.9%.
Is Indo US Bio-Tech's EV-to-EBIT too high?
Indo US Bio-Tech's current EV-to-EBIT of 12.63 is 58% below median its 10-year median of 29.77. Over the past 10 years, this metric has ranged from a low of 11.08 to a high of 60.85. The Agriculture industry median EV-to-EBIT is 12.18. Indo US Bio-Tech's value of 12.63 is 3.7% above this industry median. Based on the distribution chart, Indo US Bio-Tech ranks #110 out of 204 companies in the Agriculture industry, which is below the industry midpoint. Overall, Indo US Bio-Tech has a GF Score™ of 64/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Indo US Bio-Tech's EV-to-EBIT compare to CTVA and CF?
According to the Agriculture industry distribution chart, Indo US Bio-Tech ranks #110 out of 204 companies for EV-to-EBIT. This places Indo US Bio-Tech in the lower half of its industry. The industry median EV-to-EBIT is 12.18. Indo US Bio-Tech's value of 12.63 is 3.7% above this benchmark. Historically, Indo US Bio-Tech's own EV-to-EBIT has ranged from 11.08 to 60.85 over the past decade. While the company's 10-year median is 29.77 vs. the industry median of 12.18, Indo US Bio-Tech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for an Agriculture company?
The median EV-to-EBIT among Agriculture companies is 12.18, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Indo US Bio-Tech's current EV-to-EBIT of 12.63 is 3.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Indo US Bio-Tech and its competitors. For the Agriculture industry, the median EV-to-EBIT is 12.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Indo US Bio-Tech's current EV-to-EBIT is 12.63, which is 58% below median its own 10-year median of 29.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Indo US Bio-Tech stock overvalued right now?
Based on GuruFocus' analysis, Indo US Bio-Tech (NSE:INDOUS) is currently considered Possible Value Trap. The stock's GF Value™ is ₹297.03, compared to a current price of ₹79.09 — trading 73.4% below its estimated fair value. The current EV-to-EBIT is 12.63, which is 58% below median its 10-year median of 29.77 and 3.7% above the Agriculture industry median of 12.18. Indo US Bio-Tech's overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Indo US Bio-Tech (NSE:INDOUS), the current EV-to-EBIT is 12.63 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Indo US Bio-Tech (NSE:INDOUS) Overvalued in 2026?
Based on GuruFocus' analysis, Indo US Bio-Tech stock appears to be undervalued.
The current stock price of ₹79.09 is trading 73.4% below its estimated GF Value™ of ₹297.03.
GuruFocus considers Indo US Bio-Tech to be Possible Value Trap.
Key valuation signals for NSE:INDOUS:
EV-to-EBIT: 12.63 (58% below median its 10-year median of 29.77)
GF Value™: ₹297.03 vs. price of ₹79.09 (73.4% below fair value)
Industry Position: 3.7% above the Agriculture median (#110 of 204)
No single metric tells the full story. See the NSE:INDOUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Indo US Bio-Tech Ltd is a specialized agriculture seed company. It is involved in crop research and development through breeding, production of seeds, processing, packing, and marketing of high-performing hybrid and open-pollinated varieties of crops. The company's product portfolio includes a diversified variety of agricultural seeds, namely vegetable seeds, oil seeds, pulses seeds, cereals seeds, spices seeds used in cultivating all kinds of vegetables, pulses, crops like tomato, okra, brinjal, onion, bit root, cucumber, bottle gourd, groundnut, mustard, bajra, wheat, etc.
64GF Score
Get the complete analysis for NSE:INDOUS
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INDOUS has been successfully added to your 
